M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme.
David A. Larson,Jeffrey M. Suplica,Susan M. Chang,Kathleen R. Lamborn,Michael W. McDermott,Penny K. Sneed,Michael D. Prados,William M. Wara,M. Kelly Nicholas,Mitchel S. Berger +9 more
TL;DR: It is concluded that permanent 125I brachytherapy for recurrent or progressive glioblastoma multiforme (GM) is well tolerated and Survival time was comparable to that of a similar group of patients treated with temporary brachyTherapy.
Journal ArticleDOI
Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost.
Penny K. Sneed,Michael D. Prados,Michael W. McDermott,David A. Larson,Mary Malec,Kathleen R. Lamborn,Richard L. Davis,Keith A. Weaver,William M. Wara,Theodore L. Phillips,Philip H. Gutin +10 more
TL;DR: A retrospective review was undertaken to study the influence of age on the survival of patients undergoing brachytherapy boost for glioblastoma multiforme, and found that age was the most important parameter influencing survival.
Journal ArticleDOI
Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma
Susan M. Chang,Sarah J. Nelson,Scott R. VandenBerg,Soonmee Cha,Michael D. Prados,Nicholas Butowski,Michael W. McDermott,Andrew T. Parsa,Manish K. Aghi,Jennifer Clarke,Mitchel S. Berger +10 more
TL;DR: Metabolic and physiologic imaging characteristics provide information about tumor heterogeneity that may be important for assisting the surgeon to ensure acquisition of representative histology in newly diagnosed presumed glioma patients.
Journal ArticleDOI
Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling.
TL;DR: Estimates of the proliferative potential are important in predicting the survival of individual patients with gliomas as well as in evaluating the effectiveness of various types of treatment.
Journal ArticleDOI
Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas
Daphne A. Haas-Kogan,Anuradha Banerjee,Tina Young Poussaint,Mehmet Kocak,Michael D. Prados,J. Russell Geyer,Maryam Fouladi,Alberto Broniscer,Jane E. Minturn,Ian F. Pollack,Roger J. Packer,James M. Boyett,Larry E. Kun +12 more
TL;DR: No discordance was found among 3 approaches to defining disease progression: as interpreted by treating institutions (based on clinical status and/or imaging) and by central review (using bi-dimensional tumor "area" versus volumetric measurements).